BLISSGVS: Double-digit revenue and profit growth, strong margins, and expansion in global markets

About this update from Bliss Gvs Pharma Limited

Revenue and net profit saw double-digit growth year-over-year, with strong EBITDA margins and a net-zero debt position. Expansion in regulated and African markets, capacity investments, and digital transformation supported robust performance. Final dividend of ₹1.00 per share recommended.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bliss Gvs Pharma Limited